<?xml version="1.0" encoding="UTF-8"?>
<p id="p0200">Favipiravir is a guanine analog that is approved for influenza treatment. It can inhibit the RNA-dependent RNA polymerase of RNA viruses such as Influenza, Yellow fever, Chikungunya, Ebola 
 <xref rid="b0340" ref-type="bibr">[68]</xref>, Norovirus, and Enterovirus 
 <xref rid="b0335" ref-type="bibr">[67]</xref>. Besides, in one recent study, scientists have reported its effectiveness against 2019-nCoV 
 <xref rid="b0345" ref-type="bibr">[69]</xref>. Patients with COVID-19 are being enrolled in randomized clinical trials to test the efficacy of Favipiravir plus Interferon-Î± (ChiCTR2000029600), and Favipiravir plus Baloxavir marboxil (an approved Influenza inhibitor targeting the cap-dependent endonuclease) (ChiCTR2000029544).
</p>
